A Rollover Study of Sotorasib With or Without Panitumumab for the Treatment of Cancer Subjects With KRAS p.G12C Mutation Previously Treated in an Amgen-Sponsored Study
Amgen
Summary
The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Signed informed consent. * Age ≥ 18 years. * Life expectancy of \> 3 months, in the opinion of the investigator. * Ability to take oral medications and willing to record daily adherence to sotorasib through the use of a written diary. * Participant is currently receiving treatment with sotorasib alone or in combination therapy in an Amgen-sponsored trial that has met its endpoints or otherwise will be stopping (also referred to as parent study) and are continuing to receive clinical benefit in the opinion of the investigator. * For a participant on combination therapy in…
Interventions
- DrugSotorasib
Sotorasib will be administered orally as a tablet.
- DrugPanitumumab
Panitumumab will be administered as an IV infusion.
Locations (9)
- Florida Cancer Specialists - Fort MyersFort Myers, Florida
- University of Texas MD Anderson Cancer CenterHouston, Texas
- Scientia Clinical Research LtdRandwick, New South Wales
- Centre Leon BerardLyon
- Evangelische LungenklinikBerlin
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSRoma